- Home
- NDLS vs INKT Comparison
NDLS vs INKT Comparison
Compare NDLS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDLS | INKT |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8M | 51.7M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NDLS | INKT |
|---|---|---|
| Price | $0.71 | $12.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 626.7K | 19.9K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $494,087,000.00 | N/A |
| Revenue This Year | $2.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $4.56 |
| 52 Week High | $1.74 | $76.00 |
Technical Indicators
Market Signals| Indicator | NDLS | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 49.94 |
| Support Level | $0.76 | $11.48 |
| Resistance Level | $1.08 | $12.83 |
| Average True Range (ATR) | 0.11 | 0.82 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 20.39 | 61.48 |
Price Performance
Historical ComparisonAbout NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.